Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 92%
filed 2026-06-25
Item 5.02
The filing discloses the appointment of Pratik Trivedi as President and CEO effective July 6, 2026, along with his appointment to the Board, which is the principal disclosed action. While the filing also covers Kieran O'Sullivan's transition to Executive Chairman (a departure from CEO), the substantive focus and forward-looking impact center on Trivedi's appointment to the top executive role, including detailed compensation terms ($675,000 base salary, $2.15M long-term incentive award, and change-in-control severance provisions). This is a material executive succession event affecting investor assessment of company leadership.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-25
EX-99.1
This exhibit is a corporate presentation (investor deck) dated June 2026 disclosing Oculis' clinical development pipeline, preclinical and Phase 2 trial data for Privosegtor (optic neuritis neuroprotective candidate) and Licaminlimab (dry eye disease program), upcoming registrational milestones (PIONEER-1, PIONEER-2, PIONEER-3 trials), and financial position (cash runway into 2H 2029). The disclosure focuses on operational and clinical progress—trial designs, efficacy/safety results, regulatory designations (FDA Breakthrough, EMA PRIME, SPA agreement)—rather than a discrete event like M&A, executive change, or financial restatement. It is material because it updates investors on the status and timing of key value-driving clinical milestones and the company's pipeline advancement, which would affect a reasonable investor's assessment of the registrant's prospects.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-25
Item 5.02
The disclosure centers on amended and restated employment agreements for two named executives (CFO Conor Fennerty and Chief Investment Officer John Cattonar) that materially modify their compensation packages, including base salary increases ($600K→$650K and $500K→$550K), specified equity award targets (performance-based and time-based), and substantial backloaded restricted stock grants ($1.5M and $1.37M respectively with five-year vesting). This is a classic compensatory arrangement disclosure under Item 5.02(e), distinct from an appointment or departure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-25
Item 3.02
26North BDC issued approximately 6.3 million shares of common stock on June 24, 2026, generating $156.2 million in gross proceeds pursuant to subscription agreements with investors. The issuance was made under exemptions from Securities Act registration (Section 4(a)(2), Regulation D, and Regulation S), relying on investor representations of accredited status or non-U.S. person status. This is a classic unregistered equity issuance disclosed under Item 3.02, materially dilutive to existing shareholders and a significant capital raise for the BDC.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
SmartStop held its 2026 Annual Meeting of Stockholders on June 23, 2026, with shareholders voting on four proposals: election of six directors, advisory vote on executive compensation, frequency of future advisory votes on compensation, and ratification of BDO USA as independent auditor.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-06-25
Item 1.01
Public Storage closed a new $3.0 billion unsecured revolving credit facility, a $500 million delayed draw term loan facility, and established a $1.0 billion commercial paper program on June 25, 2026, replacing the prior $1.5 billion facility and materially enhancing the company's liquidity and financial flexibility. The new facilities total $4.5 billion in committed credit capacity and are governed by a Fourth Amended and Restated Credit Agreement with specified interest rates, maturity dates (2030-2031), and financial covenants.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-06-25
EX-99.1
This is a press release announcing Wise Group plc's full-year 2026 financial results, disclosing net revenue of $2.5 billion (up 19% YoY), income before tax of $660.4 million (26% margin), and FY2027 guidance. The document explicitly states "Wise Group plc reports Full Year 2026 Financial Results" and includes detailed financial metrics, quarterly breakdowns, and forward-looking guidance—all hallmarks of an earnings release. Material to investors as it discloses annual financial performance and strategic outlook.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-25
Item 8.01
Extra Space Storage LP entered into an underwriting agreement on June 24, 2026, to issue $550 million aggregate principal amount of 4.900% senior notes due 2032, fully guaranteed by the Company and certain subsidiaries. This is a material creation of a direct financial obligation through a public debt offering, with proceeds intended for repaying existing lines of credit, commercial paper, and general corporate purposes including acquisition funding. The transaction is clearly a debt issuance under Item 2.03 framework, disclosed here under Item 8.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-25
Item 3.02
Silver Point Specialty Lending Fund issued and sold 182,815 unregistered common shares for $5,000,000 pursuant to subscription agreements with shareholders, relying on Section 4(a)(2) of the Securities Act and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-06-25
Item 8.01
The Board of Trustees declared a regular monthly dividend of $0.24 per share payable to common shareholders as of June 30, 2026.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-06-25
Item 8.01
The filing discloses the declaration of regular and special distributions to shareholders of Class I, S, and D common shares, with specific per-share amounts ($0.21, $0.19136, and $0.20452 respectively) payable on or about July 31, 2026. This is a routine but material dividend distribution event typical of closed-end funds, affecting shareholder returns and capital allocation.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-25
Item 1.01
Mid-America Apartments, L.P. entered into a Term Loan Agreement on June 22, 2026, creating a new unsecured delayed draw term loan facility of up to $350 million (expandable to $550 million via accordion feature) maturing November 15, 2030. This is a material creation of direct financial obligation disclosed under Item 1.01, distinct from covenant breach or existing debt modification. The $350 million principal amount and syndicated lender group (KeyBank, Wells Fargo, TD Bank, JPMorgan Chase, and others) underscore materiality to a reasonable investor assessing the registrant's capital structure and leverage.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-06-25
Item 8.01
The filing announces the expiration and final results of exchange offers whereby Accendra Health exchanged approximately $478.3 million of 2029 Notes and $548.0 million of 2030 Notes for newly issued First Lien Notes ($539.25 million total) and Second Lien Notes ($698.1 million), plus a separate New Money Notes Issuance of $326.25 million in First Lien Notes. This represents a material refinancing and creation of new direct financial obligations through debt issuance and exchange, affecting the company's capital structure and financial position.
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-06-25
Item 7.01
Stifel issued a press release on June 25, 2026, disclosing selected operating results for May 31, 2026, including key performance metrics such as total client assets, fee-based client assets, loan balances, and treasury deposits. Although labeled as "operating data" rather than full earnings, the disclosure provides timely financial and operational metrics to investors and is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The CEO commentary on business performance and forward guidance further supports classification as an earnings-type disclosure.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 75%
filed 2026-06-25
EX-99.1
The exhibit announces an amended and restated credit agreement dated June 24, 2026, extending the maturity of Enerflex's syndicated secured revolving credit facility (RCF) by three years to June 30, 2029, and increasing the accordion feature from $50 million to $200 million. While this is technically an amendment to an existing facility rather than a new issuance, it represents a material modification of the Company's direct financial obligations and credit structure. The extension of maturity and enhanced borrowing capacity are significant to the Company's financial flexibility and liquidity position, warranting classification as a debt-related event. The exhibit also announces the timing of Q2 2026 earnings release, but the primary material disclosure is the credit facility amendment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-25
Item 5.07
ACRES Commercial Realty Corp. held its 2026 Annual Meeting of Stockholders on June 22, 2026, with voting results on five proposals: election of nine directors, advisory vote on named executive officer compensation, ratification of PricewaterhouseCoopers LLP as auditor, approval of approximately 7.5 million shares for the ACRES Capital Corp. merger, and adoption of the 2026 Omnibus Equity Incentive Plan.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 98%
filed 2026-06-25
Item 1.01
Agilent closed the sale of $600 million in aggregate principal amount of 4.900% Senior Notes due 2032 on June 25, 2026, pursuant to a Purchase Agreement dated June 22, 2026. The issuance includes detailed terms covering the indenture, redemption provisions, covenants, and registration rights.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders. The filing reports final voting tallies for two proposals: election of three directors (H. Michael Schwartz, Stephen G. Muzzy, and Alexander S. Vellandi) and ratification of BDO USA, P.C. as independent auditor. All three directors were elected and the auditor appointment was ratified by substantial majorities, making this a material governance event that investors rely on to assess board composition and audit oversight.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-25
Item 1.01
Taysha entered into an underwriting agreement on June 24, 2026 to issue 32.5 million shares of common stock at $6.00 per share and 833,333 pre-funded warrants at $5.999 per warrant in a registered public offering, with expected net proceeds of approximately $187.4 million (or $215.6 million with full exercise of the underwriters' 30-day option). The offering is expected to fund operations into the second half of 2028.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This is a clear disclosure of shareholder vote results from the June 24, 2026 Annual Meeting of Stockholders. The filing reports voting outcomes on three proposals: election of nine directors, ratification of Deloitte & Touche as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (shares for, against, withheld, abstained, and broker non-votes) for each proposal are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting results.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-25
EX-99.1
This exhibit presents the complete voting results from Cellectis S.A.'s Combined General Meeting of Shareholders, detailing 30 resolutions with vote tallies (For, Against, Vote Withhold), percentages, and quorum information. The resolutions cover material matters including approval of annual and consolidated financial statements, board director renewals, share buyback authorization, multiple capital increase delegations, and equity compensation authorizations. This is a classic shareholder_vote_results disclosure required under Item 5.07 equivalent for foreign private issuers.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-25
Item 5.02
Valerie Barnett, Chief Legal Officer and Corporate Secretary, is departing the Company effective June 29, 2026, following an agreement reached on June 18, 2026. This is a clear executive departure of a named officer. The filing explicitly states the termination date and confirms the separation is not due to disagreement, indicating an orderly transition. Departure of a C-suite officer is material to investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This Item 5.07 disclosure presents the results of Fulcrum's 2026 annual stockholder meeting held on June 24, 2026, including election of three Class I directors (Sonja Banks, Alan Ezekowitz, Colin Hill), advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The filing directly reports voting outcomes on these material governance matters, which is the core purpose of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 93%
filed 2026-06-25
Item 2.03
Devon Energy completed a settlement of exchange offers on June 25, 2026, issuing approximately $3.95 billion in aggregate principal amount of new senior notes across five series with maturities ranging from 2027 to 2055. The transaction involved entry into a Third Supplemental Indenture and creation of new direct financial obligations at the Devon Energy level.
View raw filing on EDGAR →
8-K
Cybersecurity Incident
confidence 95%
filed 2026-06-25
Item 1.05
The filing explicitly discloses a material cybersecurity incident under Item 1.05: unauthorized access to River Financial's network on June 16, 2026, with ransomware deployment discovered June 19, 2026. The company has taken containment measures and engaged third-party forensics to investigate potential personally identifiable information exfiltration. While the full impact remains under investigation, the incident has already impacted certain operations, making it material to investors assessing the registrant's operational continuity and data security posture.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-25
Item 2.03
TerrAscend issued $21.7 million in secured convertible debentures maturing September 30, 2031, at 8.00% interest, convertible into approximately 24.9 million common shares at $0.87 per share. The company used proceeds to retire higher-rate existing debt and retain capital for M&A purposes.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-25
Item 3.01
Heron Therapeutics received a written notice from Nasdaq on June 25, 2026, that its common shares failed to meet the minimum $1.00 per share bid price requirement for continued listing on The Nasdaq Capital Market. The company has been granted a 180-day compliance period (until December 22, 2026) to cure the deficiency, with potential for an additional 180-day period if certain conditions are met. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued market access.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This Item 5.07 discloses the final voting results from Coya Therapeutics' Annual Meeting of Stockholders held on June 25, 2026, including the election of two Class I directors (Secretary Wilbur Ross and Dieter Weinand) and ratification of Weaver and Tidwell, L.L.P. as independent auditor. The detailed vote tallies (For, Withheld, Broker Non-Votes, Against, Abstain) are the core disclosure required under Item 5.07 for shareholder meeting outcomes.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-25
Item 1.01
Ligand completed a $700 million issuance of 0.00% convertible senior notes due 2031 on June 25, 2026, in a private placement to qualified institutional buyers under Section 4(a)(2) and Rule 144A. The offering included convertible note hedge transactions and warrant transactions, with net proceeds of $678.2 million designated for general corporate purposes and share repurchases.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-25
Item 3.02
In connection with the convertible notes offering, Ligand issued warrants to purchase up to approximately 4.19 million shares of common stock, and the convertible notes may result in the issuance of up to 2.67 million shares upon conversion, representing a material dilutive capital raise through unregistered securities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from ARS Pharmaceuticals' 2026 Annual Meeting held on June 24, 2026. The filing reports voting outcomes on four proposals: election of three Class III directors (Saqib Islam, Phillip Schneider, and Laura Shawver), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency (determined to be annual). These are standard annual meeting matters that materially inform investors about board composition and governance preferences.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This is a clear disclosure of shareholder voting results from Semnur Pharmaceuticals' 2026 Annual Meeting of Stockholders held on June 25, 2026. The filing reports the outcomes of four proposals: election of a Class I director (Jay Chun, M.D., Ph.D.), ratification of Pipara & Co LLP as independent auditor, approval of the 2025 Equity Incentive Plan, and approval of the 2025 Employee Stock Purchase Plan, with detailed vote tallies for each. This is a standard Item 5.07 disclosure of shareholder meeting results, which is material to investors as it confirms governance decisions and equity plan approvals.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
Spero Therapeutics held its Annual Meeting on June 23, 2026, with stockholders voting on five matters: reelection of Class III directors (Milind Deshpande and Kathleen Tregoning), ratification of PricewaterhouseCoopers LLP as auditor, advisory vote on named executive officer compensation, amendment to increase authorized common shares from 120 million to 240 million, and approval of the 2026 Stock Incentive Plan authorizing up to 12,895,866 shares for compensatory purposes.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 82%
filed 2026-06-25
Item 1.01
Enova's subsidiary ODR 2022 amended its existing $420 million revolving receivables securitization facility on June 25, 2026, entering into Amendment No. 5 to the Credit Agreement. The amendment modifies material terms including borrowing rates, advance rates, and maturity dates extending to June 2029.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-25
Item 8.01
Apollo Debt Solutions BDC priced a $750 million offering of 6.350% notes due 2033 in a private placement to qualified institutional buyers. This is a material creation of a direct financial obligation through debt issuance, with the Fund expecting to use net proceeds for general corporate purposes and/or to repay existing indebtedness. The size and nature of the transaction clearly fall within the debt_issuance category.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-06-25
EX-99.1
This exhibit is a press release announcing OMS Energy Technologies Inc.'s fiscal year 2026 financial results for the year ended March 31, 2026. It discloses comprehensive financial metrics including revenues ($155.9M vs. $203.6M prior year), operating profit ($34.9M vs. $59.9M), net profit ($33.9M vs. $47.0M), operating cash flow ($54.1M), and EPS ($0.77 vs. $1.18), along with balance sheet and cash flow statements. The disclosure is material as it reports annual financial performance and would affect a reasonable investor's assessment of the registrant's financial condition and results of operations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 96%
filed 2026-06-25
Item 2.01
Live Oak Acquisition Corp. (a SPAC) completed a business combination with Teamshares Inc. on June 18, 2026, resulting in a change of control and the creation of a publicly traded combined company trading on Nasdaq under ticker 'TMS'. The transaction involved merger consideration of approximately $525 million, earnout provisions of up to 6 million shares contingent on stock price targets, PIPE investments, and forward purchase agreements.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-25
Item 3.02
In connection with the business combination, unregistered equity securities were issued including PIPE shares and contingent earnout shares (up to 6,000,000 shares) to Teamshares stockholders and optionholders, issued in reliance on Section 4(a)(2) exemption.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-06-25
Item 4.01
WithumSmith+Brown, PC was dismissed as Live Oak's independent registered public accounting firm on June 18, 2026, and KPMG was concurrently appointed as the new auditor in connection with the reverse recapitalization transaction.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-06-25
Item 5.02
The combined company approved and implemented three equity incentive plans: the 2026 Incentive Award Plan (5,039,004 shares, 7% of post-Closing shares), the 2026 Employee Stock Purchase Plan (1,439,715 shares, 2% of post-Closing shares), and assumed the 2020 Equity Incentive Plan, all designed to attract and retain key personnel and approved by shareholders on June 16, 2026.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-25
Item 3.02
Apollo Infrastructure Company LLC issued and sold approximately $35.5 million in unregistered equity securities across multiple share classes (Series I and Series II A-II, F-I, and I Shares) to third-party investors as of June 1, 2026, under Section 4(a)(2) and Regulations D and S exemptions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This Item 5.07 disclosure presents the final voting results from the Company's 2026 Annual Meeting of Stockholders, including the election of three directors (H. Michael Schwartz, Brent Chappell, and Stephen G. Muzzy) and ratification of BDO USA, P.C. as the independent auditor. The filing directly matches the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-25
Item 3.02
Apollo Asset Backed Credit Company LLC completed unregistered sales of equity securities totaling approximately $49.1 million across Series I and Series II share classes to third-party investors as of June 1, 2026, exempt from Securities Act registration under Section 4(a)(2), Regulation D, and/or Regulation S. The issuance of over 1.9 million shares across multiple series represents material capital raising activity that dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-06-25
Item 8.01
Apollo Asset Backed Credit Co LLC declared distributions on multiple share classes with per-share amounts ranging from $0.0835 to $0.1596, payable on July 28, 2026. The distribution declaration represents a material capital return to shareholders across Series I and Series II shares.
View raw filing on EDGAR →
6-K
M&A activity
confidence 85%
filed 2026-06-25
EX-99.1
This is a Cooperation and Development Agreement between Party A (Pet Sunshine Biological Research Co., Ltd., a Taiwan-registered entity) and Party B (Cordyceps Sunshine Biotech Holdings Co., Ltd., the Cayman Islands-registered filer). Party A grants Party B exclusive, irrevocable, worldwide rights to develop, commercialize, license, and manage the Antcin A platform (a next-generation non-steroidal anti-inflammatory drug platform) on a royalty-free basis, with 50/50 revenue sharing and preemptive/call options on future transactions. This constitutes a material strategic transaction involving transfer of exclusive commercialization and capital-markets development rights, even though legal ownership remains with Party A. The agreement explicitly contemplates future integration, M&A, and restructuring, and grants Party B substantial control over a core asset platform.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-25
Item 1.01
MoonLake entered into an underwriting agreement on June 23, 2026 to conduct a public offering of 9,000,000 Class A ordinary shares at $20.00 per share, plus pre-funded warrants and an option for underwriters to purchase an additional 1,500,000 shares. The offering is expected to generate approximately $200 million in gross proceeds. This is a material dilutive equity issuance that would significantly affect shareholder ownership percentages and is disclosed under Item 1.01 as a material definitive agreement.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-25
EX-99.1
This press release announces a significant clinical development milestone: the last patient has been successfully dosed in the Phase 2a INFORM-MS trial of intranasal foralumab for non-active secondary progressive multiple sclerosis, with topline data expected in late Q3/early Q4 2026. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company whose lead candidate is the subject of the trial, as it represents progress toward potential regulatory approval and commercialization of its primary therapeutic asset. The disclosure does not fit the specific event types (e.g., it is not an earnings release, M&A activity, or executive change), but is clearly material to investors assessing the company's pipeline advancement and clinical execution.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-25
The filing discloses a U.S. patent grant for IHL-42X in obstructive sleep apnoea with an expiry date of July 9, 2040, plus potential patent term extension eligibility. This is a material intellectual property milestone for a clinical-stage biopharmaceutical company's lead program, strengthening its competitive position and long-term exclusivity. While not fitting a specific named event type, this is clearly an operational/strategic business event—a regulatory/IP milestone—that would affect a reasonable investor's assessment of the company's asset value and development trajectory.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-06-25
EX-99.1
This is a press release dated June 25, 2026 announcing Nano-X Imaging's first quarter 2026 financial results. The exhibit discloses detailed quarterly financial metrics including revenue ($4.3M vs. $2.8M YoY), gross loss, operating expenses, and net loss ($14.3M), along with management commentary on business performance and outlook. The disclosure includes a material going-concern warning and withdrawal of 2026 revenue guidance, making this a substantive earnings announcement that would materially affect investor assessment.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-06-25
Item 7.01
The disclosure announces the death of E. Forrest Jones, Jr., who served as the Company's General Counsel (since May 2025) and as a former Board member and Director Emeritus (since March 2025). This constitutes an executive departure due to death. While the Item 7.01 classification and the "Regulation FD Disclosure" framing suggest routine disclosure, the substance is a material loss of a named executive officer and former director whose role in governance and legal affairs was significant to the organization.
View raw filing on EDGAR →